Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $645 | $499 | $423 | $535 |
| - Cash | $101 | $68 | $45 | $291 |
| + Debt | $59 | $68 | $26 | $0 |
| Enterprise Value | $603 | $499 | $404 | $243 |
| Revenue | $211 | $129 | $0 | $0 |
| % Growth | 63.4% | – | – | – |
| Gross Profit | $211 | $129 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | $51 | -$0 | -$95 | -$50 |
| % Margin | 24.1% | -0.2% | – | – |
| Net Income | $66 | -$7 | -$95 | -$51 |
| % Margin | 31.1% | -5.2% | – | – |
| EPS Diluted | 1.68 | -0.2 | -2.79 | -1.6 |
| % Growth | 940% | 92.8% | -74.4% | – |
| Operating Cash Flow | -$42 | $140 | -$94 | -$51 |
| Capital Expenditures | -$3 | -$6 | -$3 | -$5 |
| Free Cash Flow | -$45 | $134 | -$97 | -$55 |